LoadingLoadingLoading38 funds hold it.Insiders net selling.
Net selling: insiders sold $46.9M and bought $0 on the open market in 90 days (SEC Form 4). Congress: net selling of $11K to $236K in 180 days.
Analyst target and ratings are on paid plans
Unlock the full resultsLast report
Oct 21, 2026
Financial period
Third Quarter 2026
Earnings per share
$1.42 expected
Revenue
$12.99B expected
| Quarter / reported | Earnings per share | Beat or miss | Revenue / income | Revenue vs last year |
|---|---|---|---|---|
| Sep 30, 2026Reported Oct 21, 2026 | $1.42est. $1.42 | +0.03%in line | $13.01Best. $12.99B+0.18% | +14.5%from $11.37B |
| Jun 30, 2026Reported Jul 16, 2026 | $1.31est. $1.28 | +2.61%beat | $12.59BCompany release | +13.0%from $11.14B |
| Mar 31, 2026Reported Apr 16, 2026 | $1.15est. $1.15 | +0.33%in line | $11.16BSEC filing | +7.8%from $10.36B |
| Dec 31, 2025Reported Jan 22, 2026 | $1.50est. $1.49 | +0.34%in line | $11.46BAlpha Vantage | +4.4%from $10.97B |
| Sep 30, 2025Reported Oct 15, 2025 | $1.30est. $1.30 | +0.00%in line | $11.37BSEC filing | +6.9%from $10.63B |
| Jun 30, 2025Reported Jul 17, 2025 | $1.26est. $1.26 | +0.00%in line | $11.14BSEC filing | +7.4%from $10.38B |
| Mar 31, 2025Reported Apr 16, 2025 | $1.09est. $1.07 | +1.87%beat | $10.36BSEC filing | +4.0%from $9.96B |
| Dec 31, 2024Reported Jan 22, 2025 | $1.34est. $1.34 | +0.00%in line | $10.97BAlpha Vantage | +7.2%from $10.24B |
Earnings per share comes from Yahoo Finance where available, then Alpha Vantage or the company release. Revenue comes from company releases, SEC filings, Alpha Vantage or Yahoo Finance. A beat or miss needs an analyst estimate on the same basis as the reported figure, so quarters without one show none. Non-USD amounts carry their currency code.
| USD | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $11.46B | $11.16B | $12.59B | $13.01B |
| Cost of what it sold | $4.92B | $4.88B | $5.29B | $5.59B |
| Gross profit | $6.54B | $6.28B | $7.30B | $7.42B |
| What it spent | ||||
| Research and development | $735.0M | $756.0M | $882.0M | $908.0M |
| Sales and admin | $3.13B | $3.74B | — | — |
| Other operating costs | $422.0M | -$55.0M | $4.64B | $5.04B |
| Total operating expenses | $4.29B | $4.44B | $5.52B | $5.95B |
| What was left | ||||
| Operating profit | $2.25B | $1.84B | $1.78B | $1.48B |
| Interest on debt | $120.0M | $174.0M | $299.0M | $297.0M |
| Profit before tax | $2.36B | $1.45B | $1.52B | $1.23B |
| Tax | $582.0M | $372.0M | $596.0M | $311.0M |
| Net profit | $1.78B | $1.08B | $928.0M | $920.0M |
| EBITDA | $3.19B | $2.25B | $2.79B | $1.48B |
This stock is in a strong uptrend.
Trend
Strong uptrend
100 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
Coverage is bullish
Tandem Diabetes Taps GE HealthCare Exec Jeannette Bankes as CEO
NeutralNov 6Insiders Give Up US$41k As Anteris Technologies Global Stock Drops To US$5.58
NeutralNov 6We Think Stryker's (NYSE:SYK) Profit Is Only A Baseline For What They Can Achieve
NeutralNov 6Edwards Lifesciences (EW) Stock Looks Fully Priced On Cash Flow
NeutralNov 53 Dividend Kings to Buy in November and Never Sell
BullishNov 5Danaher stock gains as sepsis session shifts to recording
Leans bullishNov 5Zimmer Biomet Q3: Hips And Robotics Lift Guidance As Knees Lag; Monogram Launch Moves Up
Leans bullishNov 5Are You Overpaying For Abbott Stock Versus Its Rivals?
Leans bearishNov 530 macro signals shaping ABT right now
Unlock sector rotation, regime shifts, and macro event windows tied to this stock.
Unlock the full results
